Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB
US10519449B2 · kind B2 · utility
0Cited by
15References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 1, 2017 |
| Grant date | Dec 31, 2019 |
| Priority date | — |
| Expiry date | Feb 1, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit ANGPT2 and/or PDGFB expression and are therefore useful for treating angiogenesis-associated diseases, such as cancer, AMD, and DME.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.